We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Osmetech | LSE:OMH | London | Ordinary Share | GB00B0K29R51 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.15 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMOMH
RNS Number : 0005D
Osmetech PLC
24 November 2009
24 November 2009
Change in Details of a Director
Osmetech PLC ("Osmetech" or "the Company") (AIM: OMH) announces that it was
notified on 23 November 2009 that Jon Faiz Kayyem is no longer a Managing
Partner of Efficacy Capital Limited ("Efficacy").
Since the announcement made by the Company on 1 July 2009, Efficacy's aggregate
interest in the Osmetech ordinary 0.1p shares remains unchanged at 307,200,049.
Efficacy is the manager of the Efficacy Biotech Master Funds and Dr.
Kayyem's beneficial interest in the Efficacy Biotech Master Funds also remains
unchanged.
Consequently, Dr. Kayyem's beneficial interest in Osmetech ordinary 0.1p shares
remains unchanged and is held through the following registered holdings:
+---------------------------------+---------------+----------------+
| Registered Owner | Number of | % of issued |
| | ordinary | share capital |
| | shares | |
+---------------------------------+---------------+----------------+
| Efficacy Biotech Master Funds | 109,698,822 | 9.51% |
+---------------------------------+---------------+----------------+
| IFIN LP | 3,714,300 | 0.32% |
+---------------------------------+---------------+----------------+
| Total | 113,413,122 | 9.83% |
+---------------------------------+---------------+----------------+
Save as disclosed above, and in accordance with AIM Rule 17, there is nothing
further to disclose under Schedule Two, paragraph (g) of the AIM Rules.
For further information:
+----------------------------------+---------------------------------------------+
| Osmetech plc: | +44 (0) 20 7849 6027 |
+----------------------------------+---------------------------------------------+
| David Sandilands, Chief | |
| Financial Officer | |
+----------------------------------+---------------------------------------------+
| | |
+----------------------------------+---------------------------------------------+
| Madano Partnership: | +44 (0) 207 593 4000 |
+----------------------------------+---------------------------------------------+
| Matthew Moth | |
+----------------------------------+---------------------------------------------+
| | |
+----------------------------------+---------------------------------------------+
| Canaccord Adams Limited: | +44 (0) 20 7050 6500 |
+----------------------------------+---------------------------------------------+
| Robert Finlay | |
+----------------------------------+---------------------------------------------+
| Henry Fitzgerald-O'Connor | |
+----------------------------------+---------------------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDNFEUFELSUSEIF
1 Year Osmetech Chart |
1 Month Osmetech Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
